BUZZ-Vigil Neuroscience rises on early-stage Alzheimer's drug trial data
ReutersJan 23, 2025 2:40 PM
Shares of drug developer Vigil Neuroscience VIGL.O rise 10% to $2.25
VIGL says its experimental Alzheimer's drug, VG-3927, reduced key biomarker sTREM2 by up to 50% in cerebral spinal fluid in early-stage trial
Reduction in sTREM2 levels is expected to help slow progression of Alzheimer's disease, as higher levels suggest brain inflammation
Co says VG-3927 was well-tolerated and has favorable pharmacokinetic and pharmacodynamic profile in the trial
VIGL plans to advance into mid-stage trial in Q3 2025
8 of 9 brokerages rate stock "buy" or higher and 1 "sell"; their median PT is $16.50 - data compiled by LSEG
VIGL fell ~51% in 2024
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
16 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
